Cardiac sequelae POSTCOVID-19
DOI:
https://doi.org/10.35381/s.v.v6i1.1710Keywords:
Arrhythmias, cardiac, nursing, rehabilitation. (Source, DeCS).Abstract
Objective: To describe the cardiac sequelae in the post-COVID-19 phase. Methods: A literature review of scientific papers focused on health specifically on primary cardiac complications post-COVID-19 was performed. Results: 15 scientific papers ranging in the publication range of 2020 - 2021 with relevant contributions were selected. Conclusion: The clinical scenario may present myocardial injury, heart failure and arrhythmias occurring as a consequence of an ischemic acute coronary event. It is necessary to further study the mechanism of infection, clinical manifestations, complications to SARS-CoV-2 infection.
Downloads
References
Bardají A, Carrasquer A, Sánchez-Giménez R, et al. Implicaciones pronósticas del daño miocárdico en pacientes con y sin diagnóstico confirmado de COVID-19 atendidos en un hospital universitario [Prognostic implications of myocardial injury in patients with and without COVID-19 infection treated in a university hospital]. Rev Esp Cardiol. 2021;74(1):24-32. doi:10.1016/j.recesp.2020.08.009
Cannata F, Bombace S, Stefanini GG. Cardiac biomarkers in patients with COVID-19: pragmatic tools in hard times. Rev Esp Cardiol (Engl Ed). 2021;74(7):566-568. doi:10.1016/j.rec.2021.01.006
Calvo-Fernández A, Izquierdo A, Subirana I, et al. Marcadores de daño miocárdico en la predicción del pronóstico a corto plazo de los pacientes con COVID-19 [Markers of myocardial injury in the prediction of short-term COVID-19 prognosis]. Rev Esp Cardiol. 2021;74(7):576-583. doi:10.1016/j.recesp.2020.09.017
Calvo-Fernández A, Izquierdo A, Subirana I, et al. Markers of myocardial injury in the prediction of short-term COVID-19 prognosis. Rev Esp Cardiol (Engl Ed). 2021;74(7):576-583. doi:10.1016/j.rec.2020.09.011
Bielecka-Dabrowa A, Cichocka-Radwan A, Lewek J, Pawliczak F, Maciejewski M, Banach M. Cardiac manifestations of COVID-19. Rev Cardiovasc Med. 2021;22(2):365-371. doi:10.31083/j.rcm2202043
Lee CCE, Ali K, Connell D, et al. COVID-19-Associated Cardiovascular Complications. Diseases. 2021;9(3):47. doi:10.3390/diseases9030047
Farshidfar F, Koleini N, Ardehali H. Cardiovascular complications of COVID-19. JCI Insight. 2021;6(13):e148980. doi:10.1172/jci.insight.148980
Abou Hassan OK, Sheng CC, Wang TKM, Cremer PC. SARS-CoV-2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications. Curr Cardiol Rep. 2021;23(9):129. doi:10.1007/s11886-021-01551-x
Tetlow S, Segiet-Swiecicka A, O'Sullivan R, et al. ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19. J Intern Med. 2021;289(5):688-699. doi: 10.1111/joim.13202
Hakeam HA, Alsemari M, Duhailib ZA, et al. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study. J Cardiovasc Pharmacol Ther. 2021;26(3):244-252. doi:10.1177/1074248420976279
Li M, Wang Y, Ndiwane N, et al. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension. PLoS One. 2021;16(3):e0248652. doi:10.1371/journal.pone.0248652
Derington CG, Cohen JB, Mohanty AF, et al. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans [published correction appears in PLoS One. 2021 May 13;16(5):e0251897]. PLoS One. 2021;16(4):e0248080. doi:10.1371/journal.pone.0248080
Al Janabi T, Chinsky R, Pino MA. Perceptions of COVID-19 vaccines among osteopathic medical students (OMS). Int J Osteopath Med. 2021;42:23-28. doi:10.1016/j.ijosm.2021.10.008
Tarawneh O, Tarawneh H. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine. Am J Hematol. 2021;96(5):E133-E134. doi:10.1002/ajh.26106
Sang CJ 3rd, Burkett A, Heindl B, et al. Cardiac pathology in COVID-19: a single center autopsy experience. Cardiovasc Pathol. 2021;54:107370. doi:10.1016/j.carpath.2021.107370
Published
How to Cite
Issue
Section
License
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
